Tags » GlaxoSmithKline

Dividende von GlaxoSmithKline

Gestern erfolgte die Gutschrift der Halbjahresdividende vom britischen Pharmaunternehmen GlaxoSmithKline PLC in Höhe von 29,93 EUR. Insgesamt erhielten wir vom Unternehmen bisher 52,90 EUR an Ausschüttungen oder 3,49% auf unser eingesetztes Kapital. 37 more words


Calls for pharma to follow GSK and make drugs more accessible

Poor countries will soon be able to make their own versions of GlaxoSmithKline’s drugs without paying royalties, the UK-based pharma giant has announced.

Building on… 209 more words

GlaxoSmithKline Is One Step Closer to EU Approval for Its Gene Therapy

An European regulatory panel has recommended approval for GlaxoSmithKline’s Strimvelis, a gene therapy for the treatment of Bubble Boy disease. It would be the first children’s gene therapy approved in Europe if it receives final marketing clearance from the European Commission. 238 more words


Glaxo........Will help the world’s poorest people access copycat versions of its medicines at affordable prices.

Glaxo to Stop Seeking Drug Patents in Low-Income Countries

Drugmaker says move could help poor nations access cheaper copycat versions of its medicines

GlaxoSmithKline’s CEO Andrew Witty below… 241 more words


GlaxoSmithKline Is Expanding Drug Access to the World's Poorest Countries

British drug giant GlaxoSmithKline announced on Thursday that the company is ramping up a graduated approach to intellectual property protections on its products in an effort to expand drug access to the world’s poorest countries. 279 more words


Here’s How GlaxoSmithKline’s CEO Thinks Pharma Should Modernize

British pharma giant GlaxoSmithKline announced earlier this month that 31-year company vet Sir Andrew Witty will retire next March after eight years as CEO. That same day, Witty delivered a wide-ranging speech in front of the Center for Strategic and International Studies (CSIS) on how the pharma industry can adapt to the 21st century, controversial…



Watchdog Says U.S. Big Pharma Isn't Paying Enough for Breaking the Law

The amount of money big U.S. pharmaceutical manufacturers have paid to settle charges for violating federal health care laws has declined sharply in recent years, prompting a non-profit watchdog group to call for an increase in enforcement efforts. 367 more words